Trials / Terminated
TerminatedNCT01125358
A Study in Schizophrenic Patients
A Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 in Patients With DSM-IV-TR Schizophrenia
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 82 (actual)
- Sponsor
- Denovo Biopharma LLC · Industry
- Sex
- All
- Age
- 20 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to compare 3 doses of LY2140023 for the treatment of schizophrenia as assessed at endpoint (up to 7 weeks) using the Clinical Utility Index (CUI), a measure of efficacy, safety, and tolerability.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY2140023 | Administered orally, twice daily for up to 7 weeks of treatment |
| DRUG | Placebo | Administered orally, twice daily for up to 7 weeks of treatment |
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2012-09-01
- Completion
- 2012-09-01
- First posted
- 2010-05-18
- Last updated
- 2021-09-14
- Results posted
- 2021-09-14
Locations
22 sites across 3 countries: Japan, South Korea, Taiwan
Source: ClinicalTrials.gov record NCT01125358. Inclusion in this directory is not an endorsement.